TRT Eligibility Requirements: What You Must Prove

TRT eligibility requirements start with symptoms or signs of testosterone deficiency plus consistently low testosterone, usually confirmed with two early-morning blood tests on separate days. One low reading doesn't qualify you. A clinician must also assess the cause, health risks and fertility plans; provider access and insurance approval are separate checks. ^{1, 2}

Educational information, not medical advice. This is editorial research, not a clinician-reviewed assessment of your health.

Best for you if: you're an adult man in the U.S. with symptoms or signs of testosterone deficiency, and you're trying to find out what you actually have to prove.

Not for you if: you want a guaranteed prescription, a dose, or a way around the rules. This page won't help with any of that, and we'd rather say so now.

That's the medical answer. Here's the part almost nobody tells you: there are four more checks after that one, and the 2026 documents show why they do not always line up.

What are the five TRT eligibility requirements to check?

The five checks cover diagnosis, safety, legal access, payment and the provider’s own service rules. They are an editorial way to organize the questions below, not a medical score or a test you can use to clear yourself.

#	The check	Who decides	What it actually requires
1	Diagnosis	Your clinician, using clinical guidance	Symptoms or signs plus consistently low testosterone confirmed with appropriate repeat early-morning testing
2	Safety	Your clinician	Review of health risks, fertility plans and findings that need more evaluation before treatment
3	Legality	Federal and state law	A valid prescription for a Schedule III controlled substance from a clinician with the required authority where you are located
4	Payment	Your insurance plan — if you want one to pay	The criteria for your benefit, diagnosis and exact product
5	The provider	The clinic or platform you apply to	Its own service limits, age policy, state footprint, accepted lab records and fees

Sources: ^{1, 2, 9, 11, 12, 19}

Clearing one does not clear the others. A “no” from an insurer or clinic does not, by itself, tell you whether you meet the medical criteria. Ask which check stopped the process. A coverage problem and a medical concern need different next steps.

In June, the federal government asked drugmakers to revise testosterone labels. Twenty-five days later, Aetna re-reviewed one testosterone coverage policy and kept its age-related restriction. Three days after that, the Endocrine Society published a statement questioning how labels such as age-related hypogonadism are defined. These documents answer different questions: labeling, coverage and clinical diagnosis. ^{3, 6, 12}

So if you've been told "you don't qualify" and it didn't make sense — you're not imagining things. Five different checks can affect the answer. This page shows you all five and gives you the question to ask at each one.

This page covers evaluation for male hypogonadism, the medical term for low testosterone caused by a problem with the testicles or the hormone system that controls them. Care for women, adolescents, and people seeking gender-affirming hormones uses a different framework. ²

TRT Provider Guide is the independent decision resource for testosterone replacement therapy — helping U.S. adults understand how low testosterone is evaluated, compare online and local care models and providers, and choose the next step that fits their health needs, fertility plans, budget, state, and care preferences, with every material claim verified and dated.

The right TRT provider is not the same for every person — it depends on whether low testosterone has been properly evaluated, your symptoms and health history, your fertility plans, your state, your insurance or cash-pay preference, your treatment-format preference, your budget, and whether online or in-person care is the better starting point. Some situations belong with primary care, urology, endocrinology, reproductive urology, or urgent or emergency care when the symptoms warrant it. Because a general answer cannot resolve those for you, use TRT Provider Guide's Find My TRT Path tool to map your situation to the right care route and the questions to ask before you pay.

Not sure which of the five checks you're stuck at? Find My TRT Path → Map the care routes and questions to discuss before you pay anyone. Free, educational, and it doesn't diagnose anything.

What did we actually verify?

We compared clinical guidance, government actions, two specific insurer policies and the providers’ published disclosures. The tables show what those sources say; they do not certify a reader’s eligibility or a provider’s care.

Checked 9 September 2026. We reviewed the AUA’s published testosterone-deficiency guideline, the Endocrine Society’s 2018 guideline and its 16 July 2026 statement, the ACP’s 2020 guidance, the FDA’s 28 February 2025 labeling action, the HHS announcement of 18 June 2026, AndroGel 1.62% prescribing information, the Federal Register rule at 90 FR 61301, the VA’s January 2026 recommendations, UnitedHealthcare’s commercial medical-benefit drug policy 2026D0076J, and Aetna’s Clinical Policy Bulletin 1014. We also checked Male Excel’s FAQ, price page and terms, and Taurus Meds’ offer page, terms and refund policy. ^{2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 17, 18, 19, 20, 21, 22, 23, 38}

Provider-stated, not independently confirmed: program fees, state availability, laboratory arrangements, turnaround estimates, clinician-access promises and partner-pharmacy disclosures. A published name is not an independent license check.

What the public pages did not settle: whether either program includes both separate morning tests needed for a new diagnostic evaluation; the complete cost after required repeat testing and shipping; Taurus Meds’ full state list; and which exact product, pharmacy and clinician would be assigned to an individual. Taurus’s offer says no membership fees, while its general terms list a fee unless the purchase terms say otherwise. Get those answers in writing before you pay. ^{17, 18, 19, 20, 22}

What we did not do: examine any patient, decide anyone's eligibility, run a clinic intake, test an insurance claim, or obtain a clinician's review of this article. It's editorial research, and we'd rather label it honestly than dress it up.

Our method: How We Review TRT Providers. See our editorial standards, affiliate disclosure, privacy policy and corrections process.

Affiliate disclosure: TRT Provider Guide has affiliate relationships with Male Excel and Taurus Meds. This page contains no affiliate enrollment links. The provider examples are not a ranking or a recommendation for your care.

What testosterone level do you need to qualify for TRT?

The AUA uses total testosterone below 300 ng/dL as a reasonable cut-off in support of a diagnosis, not as a diagnosis by itself. The Endocrine Society also requires compatible symptoms or signs and consistently low results, with free testosterone checked when indicated. Your lab's reference range and the method used to measure testosterone can affect the assessment. ^{1, 2}

Let's take the confusion apart, because this is where most men get stuck.

Total testosterone is all the testosterone measured in your blood: both protein-bound and unbound. It is usually the first laboratory measure in the evaluation. ²

The American Urological Association picked 300 ng/dL as a reasonable line. The published guideline pairs that line with repeat morning testing and symptoms or signs; it does not promise that everyone below it will benefit or that everyone above it should be dismissed. ³⁸

Other groups frame the lower limit differently. The Endocrine Society points to 264 ng/dL for a testosterone assay standardized to the CDC reference method, based on healthy, non-obese young men. When SHBG is altered or total testosterone is near the lower limit, it recommends a reliable free-testosterone assessment too. That's a much narrower claim than "264 is the new 300." ^{2, 13}

Why "normal for your age" is a real thing, and also a trap

Here's a table almost nobody puts in front of patients. These are harmonized reference figures the VA cites in its January 2026 clinical recommendations, drawn from a 2017 study using a CDC reference method. They are population reference limits, not age-specific treatment thresholds. ^{5, 13}

Reference population	Lower reference limit for total testosterone
19–39 (healthy, non-obese)	264 ng/dL (reference interval 264–916)
All men 19–39	229 ng/dL
All men 60–69	190 ng/dL
All men 80–99	119 ng/dL

So when a doctor discusses age and the reference range, there is real data behind that conversation. In a hypothetical example, 240 ng/dL is above the study’s lower reference limit for all men aged 60–69 and below the AUA’s 300 line at the same time. Both comparisons are true. Neither establishes whether that person needs TRT. ^{13, 38}

Two things worth knowing before you decide who's right:

Age doesn't lower the bar by itself. The Endocrine Society's July 2026 statement is blunt about this: the approach to diagnosis and the definition are the same for a man of any age. ³
Most older men aren’t automatically low. The VA’s January 2026 review reports that about 63% of men still have testosterone inside the reference range past age 70, and that the decline often is not clinically significant. “Everyone your age is low” is marketing, not medicine. ⁵

When your lab says "normal" and the guideline says "low"

This one frustrates men constantly. Laboratories use reference populations and measurement methods that can produce different ranges, so a 250 ng/dL result may be flagged as in range by one lab. The AUA’s 300 ng/dL benchmark is not the same thing as that lab flag; a clinician still has to assess repeated results and symptoms or signs together. ^{2, 38}

If that's your situation, you're not being unreasonable. You're looking at two different definitions of the same word.

Total, free, or bioavailable — which number counts?

Free testosterone is the small fraction circulating unattached to proteins. SHBG (sex hormone-binding globulin) is a protein that binds testosterone tightly. Bioavailable testosterone generally means the free portion plus the portion loosely bound to albumin, another blood protein. ²

Total testosterone is the primary diagnostic measure in the AUA guideline. But free testosterone earns its place when total testosterone is near the lower limit, or when a condition is altering SHBG; the Endocrine Society recommends a reliable calculation or equilibrium dialysis, a laboratory measurement method, in those situations. ^{2, 38}

That second one matters more than it sounds. Keep reading — there's an insurance rule built on it that could change your outcome.

Why are two morning blood tests usually needed — and how do you make yours count?

The AUA gives a strong, Grade A recommendation to confirm low testosterone with two total-testosterone measurements on separate occasions, both early in the morning. A single measurement can be affected by timing, illness and normal biological variation. A repeat result helps a clinician decide whether the low level is consistent. ^{2, 38}

If you take one thing from this page, make it this section. It's the difference between a properly planned evaluation and an isolated number that leaves the question open.

The morning rule

Testosterone varies across the day, which is why an afternoon result cannot simply be compared with a morning result. The VA’s January 2026 guidance specifies a 6 to 10 a.m. window for its diagnostic testing. Tell the ordering clinician if you work nights or sleep at unusual hours so the collection plan fits your situation. ^{2, 5}

An afternoon low result does not, by itself, establish persistent testosterone deficiency. Ask the clinician which collection time and preparation to use before booking the draw. ²

The variability problem — and the 206-then-300 story

Repeat measurements of the same man can fluctuate enormously between tests depending on the assay used. Taking two or three measurements cuts that noise substantially. ²

Here is an illustrative example, not a patient report: a first test comes back 206 ng/dL and a repeat comes back 300 ng/dL. Those different results do not establish either a diagnosis or that a clinician has dismissed you. When results disagree, the clinician reviews collection conditions, the assay and the rest of the evaluation, and may arrange further testing. ²

Fasting: get the instructions before the appointment

The Endocrine Society recommends fasting morning draws. The VA specifies fasting too. The ordering clinician should tell you how to prepare for the specific tests being ordered. ^{2, 5}

Our practical read: follow the ordering clinician’s fasting instructions. Ask how to handle your usual medicines and health conditions; do not fast or change medication on your own because a general guide says to. ³⁵

Don't test while you're sick

Acute illness can lower testosterone temporarily. The VA also lists reversible contributors such as a large calorie deficit and some medicines, including opioids, and recommends avoiding diagnostic testosterone testing during a temporary acute illness or flare. ^{2, 5}

Tell the ordering clinician if you are sick before the test. Ask whether the testosterone evaluation should wait until you recover; that is not a reason to skip other blood work needed for the illness. ^{2, 5}

The assay question — the detail that decides borderline cases

Not all testosterone tests perform the same way, and measurement differences matter when the result is close to a decision threshold. ²

Immunoassays are widely used, but some are less precise at low concentrations. LC-MS/MS (liquid chromatography–tandem mass spectrometry) is a more specific measurement method used for testosterone testing. The method’s validation and calibration still matter. ^{2, 5}

The VA's January 2026 guidance is unusually direct: total testosterone can be measured by immunoassay first, but it says an abnormal result should be confirmed by LC-MS/MS, because immunoassays may be imprecise in the low range. That is the VA’s protocol, not a universal requirement imposed on every U.S. clinic. ⁵

And the Endocrine Society's July 2026 statement names the problem plainly: non-standardized assays can make the same sample read low at one lab and normal at another. It recommends a testosterone assay certified through the CDC’s Hormone Standardization Program. That assay certification is different from a laboratory’s CLIA certification. ³

Three questions to ask any testing route — home kit or lab draw:

Is this a venous draw or a fingerstick?
Which testosterone assay method is used, and is that assay certified through the CDC’s Hormone Standardization Program?
Can the repeat test use the same lab and method, and will the clinician who evaluates me accept both reports?

Neither a home kit nor a venous draw proves that the full diagnostic workup is complete. Ask the receiving clinician about collection, assay quality and repeat testing before paying; the laboratory brand alone cannot guarantee acceptance by another clinician or insurer. ^{2, 11, 12}

Why a symptom quiz can't do this job

An online intake often starts with a questionnaire. That's a reasonable way for a clinician to learn your history — and it's how many visits start.

But it is not the qualifying test. The AUA is explicit: validated questionnaires are not recommended to define which patients are candidates for testosterone therapy, or to monitor response. If a program treats a quiz as the thing that qualifies you, it isn't following the guideline. ³⁸

This cuts both ways, and we'll say the uncomfortable half too. If a platform is willing to approve you off a questionnaire, that's not a sign they believe in you. It's a sign they're not doing the evaluation.

You need an appropriate repeat morning-testing plan before a new diagnosis can be confirmed. A low-price intake offer is not proof that two separate diagnostic draws are included. Ask what is ordered, who reviews it, and what a repeat costs.

Review the blood-test requirements and questions to ask →

Why we point first-timers here, in plain terms: this whole page is about producing evidence that holds up. A national reference laboratory does not guarantee that another clinician or insurer will accept a particular panel. Your own doctor can arrange the evaluation too; compare the cost of the required testing and review, not just the first advertised fee. ^{2, 11, 12, 22}

What disqualifies you from TRT?

Some findings make testosterone inappropriate now; others call for more evaluation or a different care route. Fertility plans, active cancer, high red-cell levels and certain untreated health problems can change the decision. A guideline checklist does not replace a clinician’s assessment or the current label for the proposed product. ^{2, 5, 24}

Below is the list assembled from the Endocrine Society's guideline, the AUA's guideline, and the VA's January 2026 recommendations. We've split it into three tiers to show the next conversation, not to decide who can start treatment. A VA-specific rule is labeled as such; it does not become a nationwide requirement.

Tier A — A specialist or fertility-focused plan, not a clinic that ignores the issue

Condition	Why it changes the next step	Source
Currently trying to conceive, or preserving future fertility	Testosterone from outside the body can suppress sperm production. The joint AUA/ASRM infertility guideline advises against testosterone monotherapy for men interested in current or future fertility. Discuss a fertility-focused plan before TRT.	AUA/ASRM; VA
Active prostate cancer or breast cancer	The Endocrine Society recommends against starting testosterone in these situations. Cancer history and the June 2026 labeling request require specialist, product-specific review — not a blanket online clearance.	Endocrine Society; HHS
Unevaluated prostate finding, or PSA above 4 ng/mL (above 3 ng/mL with added risk factors)	The Endocrine Society calls for urologic evaluation before treatment. PSA is a blood marker used in prostate assessment; an elevated value does not itself diagnose cancer.	Endocrine Society
Thrombophilia, or a history of unprovoked blood clots	Thrombophilia means a tendency to develop blood clots. The Endocrine Society lists thrombophilia; the VA also lists prior unprovoked clots among reasons not to start under its protocol.	Endocrine Society; VA
Active, unaddressed anabolic steroid misuse	The VA lists this as a contraindication. It needs an honest clinical assessment, not another source of testosterone.	VA

Sources: ^{2, 5, 6, 24}

Tier B — Address or stabilize the condition before reconsidering TRT

Condition	What needs review	Source
High hematocrit (VA uses above 48% at baseline)	Hematocrit is the share of your blood made up of red cells. Testosterone can raise it further. The clinician investigates the cause and uses the applicable protocol.	VA; Endocrine Society
Severe, untreated sleep apnea	Untreated is the operative word. Treated apnea is a different conversation, not automatic clearance.	Endocrine Society; VA
Severe urinary symptoms (IPSS above 19)	IPSS is a urinary-symptom questionnaire score. Severe symptoms need evaluation and management before treatment is considered.	Endocrine Society; VA
Poorly controlled heart failure	Uncontrolled. Stable heart failure still requires an individual risk assessment.	Endocrine Society; VA
A recent heart attack, stroke, or revascularization procedure	Recommendations differ: AUA advises 3 to 6 months after a cardiovascular event; the Endocrine Society advises against starting within 6 months of heart attack or stroke; VA uses 4 months for the events in its protocol. These are clinician decision rules, not a choice of waiting periods for the reader.	AUA; Endocrine Society; VA
Severe liver disease or kidney failure	The VA lists these among contraindications. It specifically cautions against oral testosterone in severe liver disease; the exact product and illness need specialist review.	VA

Sources: ^{2, 5, 38}

Tier C — Findings that change the evaluation

You want kids eventually, just not now. The AUA recommends a reproductive health evaluation before treatment for men interested in fertility. Future plans still matter: the joint AUA/ASRM guideline advises against testosterone monotherapy when current or future fertility is a goal. ^{24, 38}
Breast symptoms or gynecomastia. The AUA recommends an estradiol test before treatment in this situation. Gynecomastia means enlarged breast tissue. ³⁸
You’re over 40. The AUA recommends measuring PSA before testosterone therapy. Other guidance uses age, risk and shared decision-making for prostate monitoring, so ask which approach applies. ^{2, 38}
Total testosterone under 150 ng/dL. The VA flags very low results for evaluation of a pituitary or hypothalamic cause — a problem with the glands that control testosterone. Low or low-normal LH, persistent high prolactin, or symptoms suggesting a pituitary problem can affect the need for imaging. This is a case where a fast prescription is the wrong answer and a workup is the right one. ^{2, 5, 38}
Low testosterone with high LH and FSH. LH and FSH are the pituitary’s signals to the testicles. High signals with low testosterone suggest a testicular cause. Medicines that depend on functioning testicles may have limited benefit; this is not a basis for ruling out every fertility option from two numbers. ^{2, 24}

Read the tiers, then read this: a delay is not always a permanent ban. Treating sleep apnea or finding the cause of a high hematocrit is not the end of the road. It’s the road. The next decision depends on the finding and the clinician’s assessment, not a promised six-month timeline. ^{2, 5}

Can you qualify for TRT if you want children?

Fertility plans can change whether testosterone is appropriate, even when testosterone deficiency is confirmed. The AUA advises against prescribing exogenous testosterone to men currently trying to conceive, and the joint AUA/ASRM infertility guideline advises against testosterone monotherapy for men interested in current or future fertility. Testosterone taken from outside the body can suppress the hormone signals that drive sperm production. ^{24, 38}

Spermatogenesis is the process of making sperm. Testosterone you take suppresses the pituitary signals that run it. That's the mechanism, and it isn't controversial. ²⁴

Here's what a fertility-aware evaluation actually involves, and why it belongs before you start rather than after:

The AUA recommends a reproductive health evaluation performed prior to treatment for men interested in fertility, and says the long-term impact on sperm production must be discussed. That's an eligibility requirement in its own right — not a footnote at the bottom of a consent form. ³⁸

What we will not tell you. We can’t tell you that testosterone will make you infertile. We can’t tell you it won’t. We can’t promise fertility returns on any timeline, or that any alternative protects it. What we can tell you is that this decision belongs with a reproductive urologist or a fertility-aware clinician before you start, not after you’ve been on treatment for eight months and changed your mind. ^{24, 38}

These alternatives are not TRT

You'll see hCG, clomiphene and enclomiphene marketed as fertility-friendly testosterone options. Be careful with the language, because the differences are real:

Clomiphene is FDA-approved for ovulatory dysfunction in women trying to conceive. It is not FDA-approved for male hypogonadism; that use is off-label. The VA’s January 2026 guidance notes the lack of adequately powered long-term trials in men and says it may be considered case by case for secondary hypogonadism when fertility is a goal. ^{5, 25}
hCG (human chorionic gonadotropin) is not testosterone. An FDA-approved hCG product, Pregnyl, includes selected cases of male hypogonadotropic hypogonadism among its indications. The VA restricts its use in this setting to endocrinology and infertility specialists; that is a VA rule, not a national restriction on all prescribers. ^{5, 26}
Aromatase inhibitors such as anastrozole reduce estrogen production. Anastrozole is FDA-approved for certain breast cancers in postmenopausal women, not male hypogonadism. Bone loss is a concern, and the VA does not recommend routine use for this purpose; the drug label’s ischemic-heart-disease comparison was in women with breast cancer, not a trial proving that same risk in men receiving testosterone-related care. ^{5, 28}
Enclomiphene is not FDA-approved. A compounded enclomiphene preparation is not an FDA-approved testosterone product or simply another format of TRT. ^{27, 41, 32}

None of these is “natural TRT.” None comes with a fertility guarantee. And the cause matters: clomiphene changes hormone signaling, while hCG acts more like an LH signal at the testicles. A reproductive specialist has to assess whether a treatment fits the underlying problem. ^{24, 25, 26}

If children are on your horizon, your next step isn't a subscription. It's a reproductive urologist or a fertility-aware clinician, before you start anything. Map that route with Find My TRT Path → Use it to explore care settings and the fertility questions to bring to the clinician.

There's no provider link in this section on purpose. The next decision is a fertility-focused evaluation, not which subscription to start.

For the full discussion, see our guide to TRT and fertility.

Does your age change TRT eligibility?

Age alone doesn’t decide it, and being older does not automatically qualify or disqualify you. In June and July 2026, HHS requested labeling changes, Aetna retained an age-related exclusion in a specific coverage policy, and the Endocrine Society restated its diagnostic approach. These are different decisions, not interchangeable eligibility rules. ^{3, 6, 12}

Here are those documents assembled with dates, so you can see which question each one answers.

The 2026 eligibility timeline

Date	What happened	What it means for you
28 Feb 2025	FDA’s class-wide labeling action removed boxed-warning language about increased major cardiovascular risk, added blood-pressure warnings, and retained the age-related limitation of use at that time.	A change to one safety warning did not make testosterone risk-free or approve every use. ⁷
10 Dec 2025	FDA held an expert panel on testosterone replacement therapy for men.	An expert discussion is not a change to a drug label, prescribing law or insurance benefit. ³⁶
1 Jan 2026	UnitedHealthcare’s commercial medical-benefit drug policy 2026D0076J took effect. Its standard initial lab pathway requires two low early-morning total-testosterone measurements; it also lists alternative documentation pathways.	Read the specific policy and product criteria, not just a headline threshold. ¹¹
18 Jun 2026	HHS announced that FDA was requesting removal of the age-related limitation, a prostate-cancer contraindication narrowed to metastatic disease, and changes to enlarged-prostate warnings for mild to moderate cases. The announcement cited TRAVERSE among its evidence.	This is a request, not confirmation that every product’s label has changed. ⁶
13 Jul 2026	Aetna re-reviewed CPB 1014 for testosterone cypionate. Age-related and late-onset hypogonadism remained excluded as experimental, investigational or unproven. The bulletin lists its next review as 22 April 2027.	Twenty-five days after the federal announcement, this coverage exclusion remained. ¹²
16 Jul 2026	The Endocrine Society restated the need for symptoms or signs and consistently low, accurately measured testosterone, with the same diagnostic approach across ages. It questioned the clarity of terms such as age-related, late-onset and functional hypogonadism.	An age label is not a substitute for establishing the diagnosis and its cause. ³

The takeaway, stated plainly: labeling requests and coverage decisions do not move in lockstep. We checked Aetna’s CPB 1014 on 9 September 2026 and its age-related exclusion was still there. That does not establish what every insurer covers. ^{6, 12}

That’s why “am I too old?” has no single administrative answer. Your clinician evaluates the diagnosis and treatment fit; the proposed product has its own current label; and your plan has its own coverage criteria. Ask which one the answer is about. ^{2, 6, 12}

So — too young, or too old?

Too young. Adult clinical guidance does not make a birthday alone the test for hypogonadism. But a man in his 20s or 30s with genuinely low testosterone needs the cause found, not just the number topped up. That’s why LH is a strong AUA recommendation: it helps separate a testicular cause from a pituitary one. ^{2, 38}

Platforms set their own access rules. Both Male Excel’s July 2026 terms and Taurus Meds’ terms require users to be 18 or older. That is a service-access condition, not proof that either program offers TRT to every adult who applies. ^{18, 19}

Too old. Not automatically disqualified. Individualized. The Endocrine Society suggests against routinely prescribing to all men 65 and older with low levels, while supporting case-by-case treatment after an explicit discussion of risks and benefits. The AUA recommends a baseline PSA for men over 40; the prostate-monitoring plan still needs to fit the patient. ^{2, 38}

The honest version of the risk picture

Since the June announcement leaned on TRAVERSE, here’s what that trial actually showed, including the parts the headlines skipped. It enrolled 5,246 men aged 45–80 with hypogonadism and existing cardiovascular disease or high cardiovascular risk, using 1.62% testosterone gel or placebo. Major cardiovascular events occurred in 7.0% versus 7.3%, meeting the trial’s test that testosterone was not worse than placebo by its preset margin. Pulmonary embolism — a clot in the lungs — occurred in 0.9% versus 0.5%; atrial fibrillation and acute kidney injury were also more frequent with testosterone. These findings do not establish safety for every product, population or length of treatment. ¹⁴

The fracture subtrial found clinical fractures in 3.50% versus 2.46% over a median 3.19 years. Its hazard ratio was 1.43 — a relative time-to-event measure, not a 43-percentage-point increase in a person’s fracture risk. ¹⁵

That's not a reason to avoid treatment you need. It's a reason to be skeptical of anyone selling you testosterone as risk-free because "the FDA changed its mind."

What if your labs are "normal" but you feel terrible?

Normal or borderline total-testosterone results do not explain away symptoms, but symptoms alone do not establish testosterone deficiency. The clinician needs to review the test conditions, whether free testosterone is indicated, and other possible causes. This is where a broader workup matters more than another promise of treatment. ²

Before you conclude you were brushed off, check three things:

Was the draw timed appropriately? Tell the clinician when it was collected and how you normally sleep. An afternoon result may need a properly timed repeat; it is not meaningless in every context. ^{2, 5}
Was it a single test? Ask whether the results and symptoms call for repeat morning testing. One result alone should not become a diagnosis. ^{2, 38}
Do you have a condition that alters SHBG? If so, total testosterone may not reflect free testosterone accurately in either direction. Read the insurance section below — one reviewed policy has a specific documentation pathway for this. ^{2, 11}

The obesity answer nobody wants to hear first

If low testosterone is linked to excess weight and no other cause is found, the Endocrine Society’s July 2026 statement says weight loss is typically first-line therapy. Its statement discusses appropriately diagnosed men with BMI above 27 in that setting; this is not a rule that everyone above that BMI needs testosterone treatment or is barred from it. ³

The mechanism is real and worth understanding, because it’s also good news. Obesity can suppress pituitary signals and lower total testosterone. SHBG often falls too, so free testosterone may remain normal even when total testosterone is low. The VA notes that total levels may normalize with weight loss; the outcome is not guaranteed for an individual. ⁵

We know that's not what you wanted to read. We're including it because it's true, and because a program that skips straight past it isn't doing you a favor.

The symptoms are non-specific, and that cuts both ways

Fatigue, low mood, poor concentration, reduced strength — the AUA is blunt that all of these can come from chronic stress, poor sleep, depression, or other conditions. The VA's guidance says essentially the same thing: undiagnosed chronic conditions cause many of the vaguer symptoms men attribute to low testosterone, and even one of the more specific symptoms — absent libido — can be caused by untreated chronic illness. ^{2, 5, 38}

A workup that stops at testosterone can miss thyroid disease, sleep apnea, depression and anemia. Testosterone is not a substitute for finding and treating the cause. It can improve some anemia associated with hypogonadism, which is different from being a general treatment for anemia. ^{2, 5}

One concrete example: for erectile dysfunction, PDE-5 inhibitors like sildenafil and tadalafil remain the recommended first-line treatment, because ED happens plenty often without hypogonadism. ⁵

Where the authorities genuinely split

AUA: uses a reasonable 300 ng/dL benchmark, repeat morning testing, and symptoms or signs — not a number alone. ³⁸
Endocrine Society: requires unequivocally and consistently low levels. ²
ACP (endorsed by the American Academy of Family Physicians): for age-related low testosterone specifically, suggests initiating treatment only to improve sexual function — and suggests against initiating it for energy, vitality, physical function or cognition. ⁴

Our editorial read, based on those positions: borderline labs and a wish for more energy are not a sound basis for a promised benefit. Sexual symptoms deserve a proper workup too, not automatic treatment. A program should explain what evidence supports the proposed treatment for your actual diagnosis and goal.

The VA’s own trial summary backs up that distinction. It describes a modest increase in sexual activity in the Testosterone Trials, with about a 40% increase in libido and 35% improvement in erectile dysfunction on the measures it summarizes, but no improvement on the trial’s main fatigue/vitality measure. Those are group-level research findings in older men with low testosterone, not the chance that treatment will work for you or a promised percentage improvement. ⁵

What does the law require before anyone can prescribe testosterone?

Testosterone is a Schedule III controlled substance in the United States and requires a valid prescription. Through 31 December 2026, a temporary federal rule permits qualifying telemedicine prescribing without a prior in-person exam, subject to its conditions and applicable state law. For testosterone, this is not permission to prescribe from a questionnaire alone. ^{9, 29}

Schedule III includes drugs with accepted medical use and a moderate-to-low potential for physical dependence; psychological dependence can be high. Practically, for you: a prescription is required, refill rules apply, and the clinician must have the required prescribing authority where you are physically located for care. That may involve state licensure or another state-authorized pathway, not merely being licensed somewhere in the U.S. ^{29, 30}

The date every online TRT patient should have in their head

The authority allowing telehealth prescribing without a prior in-person visit is a fourth temporary extension, published in the Federal Register at 90 FR 61301 on 31 December 2025. It took effect 1 January 2026 and runs through 31 December 2026. ⁹

A final rule titled Special Registrations for Telemedicine and Limited State Telemedicine Registrations entered White House regulatory review on 25 August 2026. The Justice Department’s agenda lists a projected final action in November 2026. Review and a projected date do not mean that rule is in effect or that its final terms are known. ^{10, 31}

A correction worth making: a proposed or pending permanent framework is not the same as an operative rule. The Federal Register record confirms that the broad prescribing flexibility described here is a temporary extension with an expiration date. ^{9, 10}

What that means for you, without the alarm: the extension preserves qualifying access during 2026, but it is not a guarantee about future appointments or refills. It is a real dated variable when choosing online or local care. And it is a fair question to put to any platform: what’s your plan if the rule changes? ⁹

Your state may say something different

The federal extension does not override state prescribing or professional-practice requirements. It requires a qualifying telemedicine encounter — generally real-time audio and video for testosterone — a legitimate medical purpose, and the required DEA and state authority. Ask the clinic what applies where you will be physically located, including any required in-person evaluation. ^{9, 30}

The practical consequence is simpler than the law: a provider’s current state list is a starting point, not proof of state law or a guarantee of an available clinician. Confirm your physical location with the provider before paying. ^{19, 30}

The state list to check on the day you apply

Male Excel's own FAQ, which we fetched on 9 September 2026, lists eleven states where its providers do not prescribe hormone treatment: Alabama, Alaska, Arkansas, Connecticut, Hawaii, Idaho, Louisiana, Minnesota, Mississippi, New Hampshire and Rhode Island. ¹⁷

That is 39 of the 50 states not listed as excluded; it does not establish availability in Washington, D.C. or U.S. territories. It also does not mean online TRT is prohibited in the eleven excluded states. ^{17, 30}

A company’s service footprint can reflect licensure, staffing and its own program limits. Check the provider’s own page the day you sign up, then confirm that it can evaluate you where you are. For the care-setting decision, see online versus local TRT care. ^{19, 30}

What does insurance make you prove before it covers TRT?

Insurance coverage is a separate check, not a substitute for a diagnosis. The two policies below have an initial pathway based on two low morning readings, but UnitedHealthcare also lists alternative documentation pathways. These are specific commercial medical-benefit policies, not rules for every plan, every product or every pharmacy benefit. ^{11, 12}

What two real policies actually say

Requirement	UnitedHealthcare — 2026D0076J, effective 1 Jan 2026	Aetna — CPB 1014, last reviewed 13 Jul 2026
Policy scope	Commercial medical-benefit policy for listed testosterone injections and Testopel pellets	Testosterone cypionate injections under commercial medical plans; other formats can fall under a pharmacy benefit or another policy
Main initial lab pathway	Two separate pre-treatment early-morning total-testosterone results under 300 ng/dL or below the lab’s reference range	At least two confirmed low morning results before treatment, based on the lab range or current practice guidelines
Documented-condition pathway	Bilateral orchiectomy (removal of both testicles), panhypopituitarism (loss of several pituitary hormones), or a genetic disorder causing hypogonadism can satisfy the specified diagnosis-related branch; other policy requirements still apply	No equivalent alternative is specified in the hypogonadism initial-approval criterion shown here
Alternative lab pathway	A condition that alters SHBG, plus one pre-treatment calculated free or bioavailable testosterone under 50 pg/mL or below the lab’s reference range	No equivalent SHBG-specific alternative is specified in this bulletin’s initial criterion
Age-related low T	Hypogonadism coverage is framed around primary or hypogonadotropic causes; confirm the applicable plan’s interpretation	Age-related and late-onset hypogonadism are excluded as experimental, investigational or unproven
Compounded testosterone	This policy classifies compounded hormone products as not proven or medically necessary for any indication	This cypionate bulletin does not establish coverage for compounded products; check the exact product and applicable policy
Authorization/continuation	Authorization is limited to no more than 12 months; a separate current-treatment lab pathway is described	A separate continuation criterion refers to a documented low morning testosterone result before treatment
Other requirements	FDA-label-consistent dosing and the relevant diagnosis-specific conditions apply; this table covers the male-hypogonadism pathway, not the separate gender-affirming-care pathway	The diagnosis must support the request; E29.1 is not covered under the listed age-related/late-onset exclusion

Sources: ^{11, 12}

Two carriers is not "most insurers." We're showing you exactly whose rules these are, and when we checked, so you can use them as a template for the questions to ask about your own plan. A medical-benefit policy for injections is not automatically the policy for a gel prescription filled at a retail pharmacy. ^{11, 12}

The SHBG rule — the paragraph that may change your outcome

Here's the one to underline.

UnitedHealthcare’s named policy allows another initial lab pathway. If a patient has a condition that can alter SHBG — the policy names thyroid disorder, HIV disease, liver disorder, diabetes and obesity — one pre-treatment calculated free or bioavailable testosterone below 50 pg/mL, or below the lab’s reference range, can satisfy that lab branch. It does not waive the other policy requirements or establish a universal clinical threshold. ¹¹

Here is the distinction that matters: low SHBG can make total testosterone look low even when free testosterone remains normal. High SHBG can produce the opposite mismatch: total testosterone may look normal while free testosterone is low. Obesity and diabetes often lower SHBG; they do not justify assuming that a normal total result is hiding low free testosterone. ^{2, 5}

The VA's guidance lands in the same place from the clinical side, listing conditions where free testosterone should be measured because total would be distorted: obesity, diabetes, glucocorticoid use, nephrotic syndrome, thyroid disease, acromegaly, androgen use, estrogen use, and liver disease. ⁵

Your action item: ask the clinician whether your condition or results make a reliable free-testosterone assessment useful. Then ask the plan which test method, units and records its policy accepts. A clinician orders and interprets the test; the policy does not do that job. ^{2, 11}

Compounded testosterone and insurance

Under the UnitedHealthcare policy reviewed here, compounded hormone products are classified as not proven or medically necessary. Separately, FDA states that compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness and quality before marketing in the way approved products are. ^{11, 32}

This matters if you're shopping online, because some programs offer compounded testosterone. FDA-approved products and compounded preparations are different things, and any page that blurs them is doing you a disservice. The named UnitedHealthcare policy excludes compounded hormone products; other benefits need their own check. A denial should be reviewed against the actual policy and its appeal process, not dismissed as something you can never appeal. ^{11, 32}

Medicare, briefly

Medicare is not one universal testosterone rule. Part B covers a limited set of outpatient drugs, often those administered by a clinician; Part D drug plans use their own formularies and coverage rules for other prescriptions. Local Coverage Determinations such as L39086 apply within a particular contractor’s scope, not to every Medicare prescription nationwide. Ask whether your proposed product and service fall under Part B or Part D. ^{33, 34}

The one thing we'd rather not tell you

Our affiliate relationships don’t change this:

Neither Male Excel nor Taurus Meds offers the insurance-billed care route described here. Male Excel’s terms explicitly exclude insurance billing, and Taurus describes its service as cash-pay. If your goal is to get your plan to pay, a cash-pay subscription is the wrong starting point. Look for in-network primary care, urology or endocrinology, online or in person, and ask about covered testing, the exact drug and any prior authorization. The clinician’s records must reflect the real diagnosis. ^{19, 22}

But understand what you’re choosing between. A cash-pay program can remove the insurer’s prior-authorization step from that purchase. It does not remove medical screening, state rules, refill decisions or the need to monitor treatment. And cash-pay does not mean the price is fixed: Male Excel lists separate fees and says prices can change; Taurus’s offer-specific purchase terms determine whether the general membership-fee provision applies. ^{18, 19, 20, 22}

Both are legitimate. Only you know which one your situation can absorb.

If you want insurance to pay, don’t start with a cash-pay subscription. Start with our guide to TRT providers that take insurance and confirm the benefit for the care and medication you need.

What do online TRT providers require?

Online programs add service rules to the medical, legal and payment checks: an age policy, a state footprint, accepted lab records and fees. A clinical evaluation still needs appropriate blood testing, and paying for an intake does not guarantee a prescription. For a new diagnosis, ask specifically how the program handles repeat morning testing. ^{2, 18, 19}

Here’s what the two programs’ public pages showed on 9 September 2026. These are examples of the fifth check — not a finding that either is the best clinical fit, and not independent verification of the services delivered.

Published requirement or disclosure	Male Excel	Taurus Meds
Company	Male Excel Inc., doing business as Excel Medical	Taurus Medical, Inc. (Delaware)
Minimum access age	18+ in the July 2026 terms; other clinical eligibility rules may apply	18+ in the terms; this is not a guarantee of treatment at 18
States not served	FAQ lists 11: AL, AK, AR, CT, HI, ID, LA, MN, MS, NH, RI	A complete state list was not confirmed from the pages reviewed; ask before paying
How you get tested	At-home finger-prick collection. FAQ names Excel Medical Labs in North Carolina and describes it as CLIA-certified; terms identify an affiliated lab as AEMA Labs. Confirm the performing laboratory and assay.	Offer page describes LabCorp or Quest Diagnostics testing, with an at-home kit at no extra charge for people more than 50 miles from those sites
Are both separate diagnostic morning tests included?	Not established by the public pages reviewed	Not established by the $49 offer page; one advertised panel is not proof of two separate collections
Turnaround	FAQ estimates about 5 business days after the lab receives the sample	Offer page estimates 1–2 weeks from testing through medication delivery; that is not a verified or guaranteed timeline
Cost to enter	Free assessment is not the full evaluation. Price page lists a $99 required consultation; obtain the current initial and repeat-test charges	The specific offer page lists $49 for blood work and a consultation; confirm that offer and all exclusions before payment
Who provides care	Terms name affiliated professional medical groups whose clinicians exercise independent judgment; the technology company is not itself the healthcare provider	Terms name OpenLoop Health, Inc. as a partner management-services organization; that name does not identify or verify the clinician assigned to you
Treatment/product clarity	Testosterone cypionate injections and a compounded Lipoderm testosterone cream are listed. The exact injection product/manufacturer must be confirmed; a cream is not an FDA-approved gel.	The offer lists several products, but its gel description incorrectly refers to intramuscular injections. Get the exact drug, format and FDA-approved-versus-compounded status in writing.
Pharmacy transparency	Reviewed FAQ does not name the dispensing pharmacy. Terms say prescriptions are filled by contracted third-party pharmacies and will not be sent to a different pharmacy.	Terms name RedRock Pharmacy (UT), Health Warehouse (KY), Precision Compounding Pharmacy (NY), and Triad Rx (AL); they do not establish which one fills an individual’s prescription
Insurance	Cash-pay; the terms say the company and medical group do not accept commercial insurance or participate in Medicare/Medicaid	Offer page describes a cash-pay model
Recurring fees	Required medical membership is $99/month, separate from medication and shipping	Offer page says $149/month with no membership fees; terms §28 list $17.99 per billing period unless otherwise stated at purchase. Ask which applies.
Follow-up and support	Membership advertises clinician e-visits and support messaging; FAQ describes PSA retesting at 6 and 12 months. Confirm the full early-monitoring plan, costs and response expectations.	Subscription policy describes provider access and online support, but says included services can vary. Confirm follow-up tests, clinician availability and urgent-contact instructions.
Refills and cancellation	FAQ describes a 60-day medication supply and a 48-hour response window after a renewal message before billing and shipment. Terms permit cancellation; get its effective date confirmed.	The February 2026 subscription policy requires a cancellation request at least 72 hours before billing to avoid the next charge
Refunds	General terms say sales/fees are non-refundable unless an exception is stated. The Excel Advantage guarantee is limited to eligible claims for the first 90 days of membership fees, with a claim deadline.	Terms say blood work is non-refundable and shipped medication sales are final. The subscription refund policy separately addresses medical-disqualification refunds. Confirm which charge each provision covers.
Medical records	Public pages reviewed do not establish the record-export process or turnaround; ask for copies of labs, visit notes and prescriptions	Public pages reviewed do not establish the record-export process or turnaround; ask for the same records

Sources: ^{17, 18, 19, 20, 21, 22, 23}

Verification limit: we did not independently verify the assigned clinicians’ licenses, the laboratory certificate or assay certification, pharmacy licenses, appointment availability, fulfillment speed or an actual cancellation. These rows report the companies’ disclosures, not a completed clinical or operational audit.

Credit where it's earned

Both companies tell you in advance that you might be told no. Taurus’s documentation and Male Excel’s terms reserve the clinical decision to the treating provider. Completing an intake is not an entitlement to a prescription; an in-person or different clinical evaluation may be needed. ^{18, 19}

Male Excel publishes medication-safety information, including warnings about secondary exposure to topical testosterone and an in-person-exam caveat. That is useful disclosure, but it is not proof that its compounded cream is FDA-approved or that the site text is the product-specific prescribing information for every prescription. Its terms also say medication shipments are not child-resistant; ask the dispensing pharmacy about packaging and safe storage. ^{19, 32}

Taurus names four partner pharmacies publicly. Naming them is useful; it does not verify their licenses or identify the pharmacy for your prescription. The offer page’s gel/injection mix-up is a reason to get the exact product in writing. Its no-membership-fee offer may override the general fee provision; confirm that in the terms for your purchase. ^{18, 22}

There is another claim to separate from the facts: Male Excel’s price page suggests insurance stops paying when testosterone reaches a normal level. The continuation provisions in the Aetna and UnitedHealthcare policies above do not support that blanket claim. Cash-pay may be a choice; it is not made necessary simply by a normal follow-up number. ^{11, 12, 20}

Three answers to get in writing before you pay

Which exact medication, and is it an FDA-approved product or a compounded preparation — and which pharmacy dispenses it? A catalogue can contain both approved products and compounded preparations. Get yours named, with its treatment format and product-specific instructions. ³²
What’s the total recurring cost, including any separate membership fee? Include initial and repeat testing, visits, medicine, supplies, shipping and the renewal schedule. For Taurus, confirm that the actual purchase terms include the offer’s no-membership-fee statement. ^{18, 20, 22}
What happens if I’m not approved, and what’s refundable? A refund of a subscription is not necessarily a refund of completed blood work or shipped medicine. For Male Excel’s guarantee, confirm eligibility and its deadline; for Taurus, clarify the medical-disqualification refund and the 72-hour cancellation cutoff. ^{18, 19, 21, 23}

What the advertised numbers add up to — and what they leave out

There is no single national “cost to qualify.” The total depends on the visits and tests actually needed, the payment route and what the program includes. For these two examples, a complete first-year bill cannot be confirmed from the reviewed public pages alone.

Published offer	Twelve-month arithmetic, not a complete quote	Still unresolved or additional
Male Excel injection-plus-thyroid bundle starting at $120/month, plus $99/month membership and the listed $99 consultation	12 × ($120 + $99) + $99 = $2,727	Initial/repeat testing, shipping/handling, any applicable taxes, dose-related price changes and whether the consultation is credited
Male Excel compounded-cream-plus-thyroid bundle starting at $132/month, with the same membership and consultation	12 × ($132 + $99) + $99 = $2,871	The same unresolved items; this is a compounded cream bundle, not a price for an FDA-approved gel
Taurus’s specific $49 intake offer plus advertised $149/month treatment	$49 + (12 × $149) = $1,837	Whether the $17.99-per-billing-period term applies, the billing period, repeat-test inclusion and any offer exclusions

These calculations assume one intake/consultation, twelve advertised monthly price equivalents at unchanged rates, and no credit or discount. Male Excel’s medication bundles are billed as 60-day supplies; its membership is monthly. Actual refill dates can change which charges fall within the first 365 days. These are published-component subtotals, not complete first-year costs or promises of approval. ^{18, 20, 22}

The Male Excel bundles shown include thyroid medicine. Thyroid treatment requires its own medical reason; it is not a standard requirement for TRT eligibility. Its lower-priced clomiphene-containing Triclozene offer is not testosterone replacement. ^{25, 37}

Once a clinician has resolved diagnosis, safety and fertility, the next question is which care setting and treatment format fit your life. Compare the monitoring, product, pharmacy and complete cost — not just the signup price.

Use Find My TRT Path to organize your care-route questions →

Why we point the treatment-ready reader here: the public pages do not establish a complete individual price or clinical fit. More than one treatment format can be useful, but that fact alone does not make a provider the best choice. Compare treatment formats and TRT costs after the clinical questions are answered.

For the step-by-step process once you've chosen, see how to get TRT online.

What should you do if you’re told you don’t qualify?

Ask one question first: what was the “no” actually about? Missing evidence, a health concern, the clinic’s limits and the insurance plan can call for different next steps. Get the reason and your records in writing so another clinician or the plan can review the actual issue.

Here's how to sort it.

If the “no” was about…	Ask this	The actual next step
The evidence — the workup is incomplete	“What evidence is missing, and who arranges it?”	The clinician identifies needed repeat testing or cause evaluation, such as LH/FSH or free testosterone when indicated. Missing evidence is not an automatic verdict.
Your health — a finding or history	“Does any part of my history need specialist review before this is reconsidered?”	Address the finding with the appropriate clinician. Don’t shop for someone willing to ignore it.
The clinic — state, services or scope	“Is this a rule about me, or about what this clinic can offer?”	A different care route may fit, but any prescriber still needs the required legal authority and a sound clinical assessment.
The plan — coverage, not diagnosis	“Which specific policy and which criterion were not met?”	Get the policy and denial in writing. Ask about missing documentation and the applicable appeal process, separately from deciding what care you need.

Sources: ^{2, 9, 11, 12}

One thing to be careful about. If the answer was about safety, that isn’t an obstacle to route around. A qualified second opinion can be useful, and clinicians can reasonably differ. The second clinician needs the findings and a reasoned plan — not just an agreement to prescribe.

And one worth saying out loud. A 2018 VA Office of Inspector General report found major gaps in documented evaluation among the VA patients it studied using fiscal-year 2014 records. For VA-initiated therapy, it estimated that only 9.1% had the specified repeat morning test before treatment. That is a dated VA finding, not a statistic about all clinics or men today. A clinician who wants a second test isn’t stonewalling you. They’re doing the thing that was missing. ¹⁶

Already on TRT and switching clinics?

The rules for continuing treatment can differ from the rules for starting it. A new provider may still need your original lab reports, treatment history and recent monitoring; an insurer’s continuation wording does not decide what that clinician must do. ^{5, 11, 12}

Two concrete examples of how the standard shifts:

Aetna's CPB 1014 requires at least two confirmed low morning testosterone levels before starting therapy. For continuation, it asks that the member had a confirmed low morning testosterone level before therapy started — singular. ¹²
UnitedHealthcare’s named policy includes a current-treatment pathway using a calculated free or bioavailable testosterone level from the past 6 months for patients treated under a year, or 12 months for those treated a year or longer. The result must be within or below the reporting lab’s male limits, or above those limits with a clinician-directed dose adjustment. Other policy conditions still apply. ¹¹

So the record that matters most is your pre-treatment result — the one from before you ever started. If you have it, get a copy now. Ask the original clinic for the lab report with the date, collection time, units and reference range on it. ⁵

If you don't have it, say so honestly at intake. VA clinicians work from a written protocol for exactly this situation — men on testosterone without documented hypogonadism — and it involves clinical judgment about duration of use and whether symptoms improved. ⁵

What you should not do is stop or change treatment on your own based on anything you read here. That includes this page. Bring the question to the receiving clinician and let them plan it.

You qualified. What are you actually signing up for?

TRT requires ongoing review, not just an initial approval. The clinician monitors response, testosterone and red-cell levels, with blood-pressure and prostate assessment as appropriate for the person and product. Follow-up timing varies, and treatment should be reconsidered when benefits do not justify the risks or symptoms do not improve. ^{2, 5, 7, 38}

What gets watched. The VA recommends early follow-up at 3 to 6 months and again at 12 months. Its protocol gives clinicians hematocrit action points above 51% and 54%; these are instructions for clinical review and management, not numbers for changing treatment yourself. The Endocrine Society recommends urologic consultation for a confirmed PSA rise above 1.4 ng/mL over baseline in the first year, a confirmed PSA above 4 ng/mL, or an abnormal prostate exam. Prostate testing depends on the monitoring plan agreed with the clinician, not automatic lifelong annual screening for everyone. ^{2, 5}

Timing your blood draws matters. The VA describes mid-interval testing for some injectable regimens and a post-application window for some gels. Those are not universal instructions: AndroGel 1.62% labeling uses a pre-dose morning testosterone measurement for its specified monitoring. Ask your clinician to write down the timing for your exact product and prescribed schedule — this is one reason follow-up numbers can be hard to compare. ^{5, 8}

The stopping conversation nobody puts in the ads. The AUA says clinicians should discuss stopping therapy 3 to 6 months after starting in men whose testosterone normalized but whose symptoms didn't improve. The VA recommends discontinuation if, after 6 to 12 months, testosterone is in range but symptoms haven't meaningfully and consistently improved. The ACP says the same for age-related low testosterone and sexual function. ^{4, 5, 38}

Read that again if “is this forever?” has been nagging at you. The guidelines call for reassessment when treatment isn’t helping. That isn’t a promise that everyone can stop without a plan. It is a reason to agree on follow-up and goals with the clinician. ^{2, 4, 38}

And the insurance clock. The UnitedHealthcare policy reviewed here authorizes no more than 12 months at a time. Your plan may approve a shorter period or use different rules. Ask for the actual authorization end date and renewal requirements rather than assuming a full year. ¹¹

What else should you know about TRT eligibility?

These questions separate clinical eligibility from testing, access and payment rules. Use them to prepare a conversation, not to decide on your own that a number or a symptom qualifies you.

What are the TRT eligibility requirements? Symptoms or signs of testosterone deficiency, plus consistently low testosterone confirmed by appropriate repeat early-morning testing. The AUA uses below 300 ng/dL as a reasonable supporting cut-off, not a diagnosis by itself. Safety, fertility, legal access, your payment route and the provider’s own service rules are separate parts of the decision. ^{2, 38}

What testosterone level qualifies for TRT? No number qualifies you by itself. The AUA uses below 300 ng/dL as a reasonable diagnostic benchmark; the Endocrine Society cites a 264 ng/dL lower reference limit for CDC-standardized assays based on healthy, non-obese young men. The age-group values in the reference table describe populations, not age-specific permission to start TRT. ^{2, 13, 38}

Do I really need two blood tests? For a new AUA-guided diagnosis, two separate early-morning total-testosterone measurements are recommended because one result does not establish consistently low levels. The insurer examples are not identical: UnitedHealthcare’s named policy also has documented-condition and free/bioavailable-testosterone pathways. A coverage exception is not permission to skip the clinical evaluation. ^{11, 38}

Can a symptom questionnaire qualify me? No. The AUA does not recommend using validated questionnaires to decide who's a candidate for testosterone therapy. A questionnaire is a starting point for a clinician, not a qualifying test. ³⁸

What disqualifies you from TRT? Fertility plans, active prostate or breast cancer, unevaluated prostate findings, high hematocrit, severe untreated sleep apnea and other significant health concerns can make TRT inappropriate or require more evaluation. Some findings can be addressed; others need ongoing specialist care. The clinician must apply the relevant guidance and product label rather than treating the three tiers as a self-clearance checklist. ^{2, 5, 24}

Is there a minimum age for TRT? A birthday alone does not establish adult hypogonadism or treatment suitability. Both Male Excel’s and Taurus Meds’ terms require users to be 18 or older, but that service-access rule does not guarantee TRT eligibility. Adolescents need a different, specialist evaluation. ^{2, 18, 19}

Am I too old to qualify? Age does not automatically disqualify you. The Endocrine Society’s July 2026 statement says the diagnostic approach is the same across ages; its clinical guideline advises against routinely treating all men 65 and older with low levels, in favor of individual assessment. ^{2, 3}

Did the rules change in 2026? Partly. In June 2026, HHS through the FDA requested that manufacturers remove the label limitation about age-related low testosterone and narrow the prostate cancer contraindication to metastatic disease. That's a request, not proof every label has changed — and when we checked in September 2026, Aetna's policy still excluded age-related hypogonadism. ^{6, 12}

Can I qualify if my levels are "normal"? A normal or borderline total result can need further assessment when symptoms persist, collection conditions were unsuitable or SHBG is altered. That is not a diagnosis and does not guarantee treatment. Ask the clinician whether repeat testing, a reliable free-testosterone assessment or evaluation for another cause is indicated. ²

Does wanting children disqualify me? It can change whether testosterone is appropriate now or at all. The joint AUA/ASRM guideline advises against testosterone monotherapy for men interested in current or future fertility. Discuss your plans with a reproductive urologist or fertility-aware clinician before treatment; neither TRT nor an alternative comes with a fertility guarantee. ²⁴

What does insurance require? Your specific plan, benefit, diagnosis and product determine the paperwork. The two reviewed policies include a two-low-morning-result pathway, but UnitedHealthcare also allows specified alternatives, including a calculated free or bioavailable result under 50 pg/mL or below the lab’s reference range when a condition alters SHBG. Other requirements still apply. ^{11, 12}

Will insurance cover compounded testosterone? The UnitedHealthcare commercial medical-benefit policy reviewed here excludes compounded hormone products as not proven or medically necessary. That does not establish the rule for every plan or benefit. Compounded preparations are not FDA-approved; check the exact prescription and policy rather than assuming coverage or that an appeal is unavailable. ^{11, 32}

Can I legally get testosterone online? Yes, qualifying patients can receive a lawful prescription through telemedicine. Testosterone remains Schedule III, and the temporary federal extension runs through 31 December 2026, subject to the encounter, DEA and state requirements. It does not guarantee that an online-only evaluation is available or sufficient for you. ^{9, 29, 30}

Which states can't get online TRT? There is no single provider list that answers that legal question. Male Excel’s FAQ lists eleven states it does not serve, but that is its service footprint, not a ban on all online TRT in those states. Ask about the clinician’s authority and availability where you will be physically located. ^{17, 30}

What labs are run besides testosterone? The cause and safety workup may include LH and FSH, with prolactin when testosterone is low and LH is low or low-normal. The AUA also recommends hemoglobin/hematocrit before treatment, PSA for men over 40, and estradiol when there are breast symptoms. The clinician chooses the panel; not every patient needs every hormone test. ^{2, 38}

Do I have to stay on it forever? Not automatically. The AUA, the VA and the ACP all describe a scheduled re-evaluation, and all three say to discuss stopping if your levels normalized but your symptoms didn't improve. ^{4, 5, 38}

Does paying cash remove the requirements? No. Paying cash changes who pays. It doesn't establish a diagnosis or create an entitlement to a prescription, and testosterone remains a controlled substance either way. ^{2, 29}

What should you do before you pay for an evaluation?

First, gather the test reports and clinical records you already have, then ask what is still needed. For a new diagnosis, the clinician should plan appropriate repeat morning testing rather than treating one result or a quiz as proof. ^{2, 5, 38}

Copy these questions for the appointment:

“Which of the five checks is unresolved: diagnosis, safety, legal access, payment or the provider’s service rules?”
“What records or repeat tests do you need, and do my fertility plans change the next step?”
“What will I pay if treatment is not appropriate, and what is the complete cost if it is?”

Bring existing lab reports with dates, collection times, units and reference ranges; your medicine and supplement list; and any relevant prior treatment or insurance records. The point is to close the missing question, not to buy tests twice. ⁵

A note on urgent symptoms. Call 911 for chest pain, sudden trouble breathing, stroke symptoms or sudden loss of vision rather than pursuing hormone treatment. A new painful or swollen leg needs prompt medical assessment; with chest pain, breathlessness or fainting, seek emergency help. ^{39, 40}

Still not sure which TRT care route fits you? Use our free Find My TRT Path tool.

Which sources support this page?

All sources were checked on 9 September 2026. Clinical recommendations, product labels and payer documents have different scopes; company pages are identified below as provider-published information.